HIV
HIV-1 is an RNA retrovirus that infects immune cells through the envelope glycoprotein Env, whose mature gp120/gp41 trimer mediates viral entry into host cells[1]. Mechanistically, gp120 binds CD4 and then the chemokine coreceptors CCR5 or CXCR4, while gp41 refolding brings viral and cellular membranes together for fusion[2][3]. After entry, viral replication depends on reverse transcriptase, protease, and integrase, making these enzymes core targets for antiretroviral research[4][5]. In disease relevance, untreated HIV replication causes progressive CD4+ T-cell loss and immunological abnormalities, increasing infectious and oncological complications[6]. Compared with related forms, HIV-1 remains the main focus because it is described as the most virulent and pathogenic subtype in diagnostic and treatment literature[7]. For experimental applications, entry inhibitors target gp120, gp41, CCR5, or CXCR4, while enzyme inhibitors target reverse transcriptase, protease, or integrase to suppress distinct stages of the HIV life cycle[4][8].
References:
- [1]. Anang S, et al. Characterization of full-length and cytoplasmic tail-truncated envelope glycoproteins incorporated into human immunodeficiency virus (HIV-1) virions and virus-like particles. J Virol. 2025 Dec 23;99(12):e0158525. [Content Brief]
- [2]. Teixeira C, et al. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug. Eur J Med Chem. 2011 Apr;46(4):979-92. [Content Brief]
- [3]. Princen K, et al. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev. 2005 Dec;16(6):659-77. [Content Brief]
- [4]. De Clercq E. Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005 May;10(2):241-73. doi: 10.1517/14728214.10.2.241. PMID: 15934866. et al. Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005 May;10(2):241-73. [Content Brief]
- [5]. Palmisano L. Role of integrase inhibitors in the treatment of HIV disease. Expert Rev Anti Infect Ther. 2007 Feb;5(1):67-75. doi: 10.1586/14787210.5.1.67. PMID: 17266455. et al. Role of integrase inhibitors in the treatment of HIV disease. Expert Rev Anti Infect Ther. 2007 Feb;5(1):67-75. [Content Brief]
- [6]. Deeks SG, et al. HIV infection. Nat Rev Dis Primers. 2015 Oct 1;1:15035. [Content Brief]
- [7]. Zulfiqar HF, et al. HIV Diagnosis and Treatment through Advanced Technologies. Front Public Health. 2017 Mar 7;5:32. [Content Brief]
- [8]. Greenberg M, et al. HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol. 2004 Sep-Oct;14(5):321-37. [Content Brief]
All Product Categories
-
HIV Related Products (907)
Related Products (907)
-
Kuguacin N
0 ImagesCat. No.: HY-N10671CAS No.: 1141453-73-7Kuguacin N is a natural product that could be isolated from the vines and leaves of M. charantia. Kuguacin N has antiviral activity.
-
2F5 epitope
0 ImagesCat. No.: HY-P4020CAS No.: 470704-11-12F5 epitope, a peptide gp41 (659-671), comprises the entire epitope for one of the three known antibodies capable of neutralizing a broad spectrum of primary HIV-1 isolates and is the only such epitope that is sequential. 2F5 epitope is recognized by broadly neutralizing antibodies 2F5.
-
(threo)-Indinavir
0 ImagesCat. No.: HY-B0689CCAS No.: 360558-79-8Synonyms: (threo)-MK-639; (threo)-L735524(Threo)-Indinavir is a protease inhibitor that plays an important role in HIV/AIDS suppression. (Threo)-Indinavir is used as a component of highly active antiretroviral suppression. By inhibiting the viral protease, (threo)-Indinavir ((threo)-MK-639) is able to effectively block the replication of the HIV virus.
-
Influenza antiviral conjugate-1
0 ImagesCat. No.: HY-148202CAS No.: 2567770-65-2
-
Kadsuralignan A
0 ImagesCat. No.: HY-N11939CAS No.: 913237-64-6Kadsuralignan A (compound 1) is a dibenzocyclooctadiene lignan isolated from the leaves and stems of Schisandra lancifolia. Kadsuralignan A has anti-HIV activity with EC50=2.23 μg/mL.
-
Niruriside
0 ImagesCat. No.: HY-165513CAS No.: 173268-90-1Niruriside is a HIV REV/RRE complex inhibitor. Niruriside specifically inhibits the binding interaction between HIV REV protein and RRE RNA, with an IC50 of 3.3 μM, and shows no significant activity against the unrelated R17 capsid protein/operator RNA binding system. At the tested concentrations, Niruriside fails to protect CEM-SS cells from acute HIV-1 infection. Niruriside can be used in the research of human immunodeficiency virus (HIV) infection.
-
4-Isocyanato-TEMPO,Technical grade
0 ImagesCat. No.: HY-W777072CAS No.: 88418-69-34-isocyanato TEMPO is a spin labeling reagent used to label the 2’-position in RNA. It has been used to study HIV-1 transactivation response RNA and hammerhead ribosome dynamics by electron paramagnetic resonance (EPR) spectroscopy.
-
L 696229
0 ImagesCat. No.: HY-105207CAS No.: 135525-71-2L 696229 is a specific inhibitor ofhuman immunodeficiency virus type 1 (HIV-1)reverse transcriptase (RT) activity that possesses antiviral activity.
-
(Rac)-Saphenamycin
0 ImagesCat. No.: HY-126924CAS No.: 634600-55-8(Rac)-Saphenamycin (compound CID_134184) is a gp41 inhibitor with anti-HIV-1 activity. (Rac)-Saphenamycin reveals p-p interactions with Trp571.
-
(Cys47)-HIV-1 tat Protein (47-57)
0 ImagesCat. No.: HY-P2493CAS No.: 627079-23-6(Cys47)-HIV-1 tat Protein (47-57) has membrane translocation function and can be used to derivatize the surface of magnetic pharmaceuticals and substantially facilitated their uptake into target cells.
-
HGS101
0 ImagesCat. No.: HY-P991541HGS101 is a fully human CCR5 monoclonal antibody with high affinity to CCR5. HGS101 binds to the 2nd extracellular loop (ECL-2) and acts as a signal antagonist. HGS101 restores Maraviroc (HY-13004) inhibition of Maraviroc-resistant HIV-1 infection of PBMCs. HGS101 shows anti-HIV activity by inhibiting CCR5 signaling in simian immunodeficiency virus-uninfected RMs models.
-
Vicriviroc malate
0 ImagesCat. No.: HY-B0155BCAS No.: 541503-81-5Synonyms: SCH 417690 malate; SCH-D malate; MK-7690Vicriviroc (SCH 417690) malate is an orally active CCR5 antagonist with the IC50 of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC50 values of 0.91 nM and 16 nM,,respectively. Vicriviroc malate can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer.
-
Bictegravir-d4
0 ImagesCat. No.: HY-17605S2Synonyms: GS-9883-d4Bictegravir-d4 is a deuterium of Bictegravir (HY-17605). Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
-
Murabutide
0 ImagesCat. No.: HY-106055CAS No.: 74817-61-1Murabutide is an immunomodulator and also a NOD2 receptor agonist. Murabutide enhances the signal transduction of ATR and NOD2, mediates the activation of the DDR pathway, and thereby repairs radiation-induced DNA double-strand breaks. Murabutide inhibits radiation-induced cell apoptosis and protects cells and mice from radiation-induced toxic damage. Murabutide induces the expression and DNA-binding activity of Oct-1 in macrophages, thereby inhibiting the transcription and replication of HIV-1. Murabutide reduces the expression levels of CD4 and CCR5 on the surface of macrophages, and induces the secretion of β-chemokines, TNF-α and IL-6. Murabutide enhances non-specific viral resistance and targets reticuloendothelial cells. Murabutide can be used in research related to radiation-induced damage and human immunodeficiency virus type 1 infection.
-
Interiorin
0 ImagesInteriorin can be isolated from Kadsura heteroclita and has moderate anti-HIV activity with an EC50 value of 1.6 lg/mL.
-
HIV gp120 (308-331)
0 ImagesCat. No.: HY-P10250CAS No.: 115416-08-5
-
UC-38
0 ImagesCat. No.: HY-105491CAS No.: 135812-34-9Synonyms: NSC-629243UC-38 (NSC-629243) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with anti-HIV activity.
-
HIV-1 inhibitor-35
0 ImagesCat. No.: HY-147552CAS No.: 2416971-32-7
-
Atazanavir-d6
0 ImagesSynonyms: BMS-232632-d6Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM.
